-
Something wrong with this record ?
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO
I. Avivi, L. Arcaini, VV. Ferretti, A. Boumendil, H. Finel, G. Milone, F. Zaja, D. Liliana, M. Musso, B. Didier, E. Bachy, M. Wattad, E. Nicolas-Virelizier, M. Gramatzki, JH. Bourhis, D. Caillot, A. Haenel, G. Held, C. Thieblemont, P. Jindra, D....
Language English Country England, Great Britain
Document type Journal Article
PubMed
29984825
DOI
10.1111/bjh.15454
Knihovny.cz E-resources
- MeSH
- Survival Analysis MeSH
- Transplantation, Autologous MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphoma, B-Cell, Marginal Zone diagnosis therapy MeSH
- Follow-Up Studies MeSH
- Treatment Failure MeSH
- Prognosis MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Retrospective Studies MeSH
- Hematopoietic Stem Cell Transplantation methods MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
The role of autologous stem cell transplantation (ASCT) in patients with marginal zone lymphoma (MZL) is debatable. This study investigated the outcome and prognostic factors affecting the outcome of patients undergoing ASCT for MZL. Eligible patients had non-transformed nodal, extra-nodal (MALT) or splenic MZL (SMZL), aged ≥18 years, who underwent a first ASCT between1994 and 2013 and were reported to the European Society for Blood and Marrow Transplantation, Fondazione Italiana Linfomi or Gruppo Italiano Trapianto Di Midollo Osseo registries. The study included 199 patients, [111 MALT lymphoma, 55 nodal MZL (NMZL) and 33 SMZL]. Median age at transplantation was 56 years. The median number of prior therapies was 2 (range 1-8), including rituximab in 71%. 95% had chemosensitive disease. 89% received a chemotherapy-based high-dose regimen. There were no significant differences in patient and transplant characteristics between the 3 histological subtypes except for a lower percentage of patients previously treated with rituximab in the MALT sub-group and more transplants performed in recent years in the other sub-groups. After a median follow-up of 5 years, 5-year cumulative incidence of relapse/progression and non-relapse mortality were 38% and 9%, respectively. Five-year event-free survival (EFS) and overall survival (OS) were 53% and 73%, respectively. Five-year cumulative incidence of second malignancies was 6%. Multivariate analysis revealed age ≥65 years was associated with a shorter EFS and OS. In addition, patients with SMZL had a shorter OS than those with MALT. ASCT may provide clinical benefit in MZL patients who have failed multiple lines of chemoimmunotherapy.
APHP INSERM U 728 Institut Universitaire d'Hematologie Hopital Saint Louis Paris France
Brest University Hospital Brest France
Centre Léon Bérard Lyon France
Charles University Hospital Prague Czech Republic
CHU de Dijon Hospital `Le Bocage` Dijon France
Département d'Onco Hématologie Institut Paoli Calmettes Marseille France
Department of Haemato Oncology St Bartholomew's Hospital Barts Health NHS Trust London UK
Division of Medical Oncology Istituto Nazionale dei Tumori Milan Italy
DRMM University of Udine Udine Italy
EBMT LWP Paris Office Hôpital Saint Antoine Paris France
EBMT LWP Paris Office Hôpital Saint Antoine Paris France University of Heidelberg Heidelberg Germany
Inserm U935 CHU de Poitiers Poitiers France
Institut Gustave Roussy Villejuif France
Institute of Hematology University of Catania Catania Italy
IRCCS Fondazione Policlinico San Matteo Pavia Italy
Kliniken Essen Süd Essen Germany
Klinikum Chemnitz gGmbH Chemnitz Germany
Midizinische Klinik und Poliklinik 1 Universitaetsklinikum Dresden Dresden Germany
National Institutes of Health National Cancer Institute Bethesda MD USA
Oncoematologia e TMO Palermo Italy
Ospedale degli Infermi Biella Italy
Tel Aviv Sourasky Medical Centre Tel Aviv Israel
Universita Di Pavia IRCCS Fondazione San Matteo Pavia Italy
University Hospital Pilsen Czech Republic
University Hospital Schleswig Holstein Kiel Germany University of Kiel Kiel Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035136
- 003
- CZ-PrNML
- 005
- 20191008112817.0
- 007
- ta
- 008
- 191007s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.15454 $2 doi
- 035 __
- $a (PubMed)29984825
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Avivi, Irit $u Tel Aviv Sourasky Medical Centre, Tel-Aviv, Israel.
- 245 10
- $a High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO / $c I. Avivi, L. Arcaini, VV. Ferretti, A. Boumendil, H. Finel, G. Milone, F. Zaja, D. Liliana, M. Musso, B. Didier, E. Bachy, M. Wattad, E. Nicolas-Virelizier, M. Gramatzki, JH. Bourhis, D. Caillot, A. Haenel, G. Held, C. Thieblemont, P. Jindra, D. Pohlreich, F. Guilhot, F. Kroschinsky, B. Wahlin, C. Scheid, N. Ifrah, C. Berthou, P. Dreger, S. Montoto, A. Conconi,
- 520 9_
- $a The role of autologous stem cell transplantation (ASCT) in patients with marginal zone lymphoma (MZL) is debatable. This study investigated the outcome and prognostic factors affecting the outcome of patients undergoing ASCT for MZL. Eligible patients had non-transformed nodal, extra-nodal (MALT) or splenic MZL (SMZL), aged ≥18 years, who underwent a first ASCT between1994 and 2013 and were reported to the European Society for Blood and Marrow Transplantation, Fondazione Italiana Linfomi or Gruppo Italiano Trapianto Di Midollo Osseo registries. The study included 199 patients, [111 MALT lymphoma, 55 nodal MZL (NMZL) and 33 SMZL]. Median age at transplantation was 56 years. The median number of prior therapies was 2 (range 1-8), including rituximab in 71%. 95% had chemosensitive disease. 89% received a chemotherapy-based high-dose regimen. There were no significant differences in patient and transplant characteristics between the 3 histological subtypes except for a lower percentage of patients previously treated with rituximab in the MALT sub-group and more transplants performed in recent years in the other sub-groups. After a median follow-up of 5 years, 5-year cumulative incidence of relapse/progression and non-relapse mortality were 38% and 9%, respectively. Five-year event-free survival (EFS) and overall survival (OS) were 53% and 73%, respectively. Five-year cumulative incidence of second malignancies was 6%. Multivariate analysis revealed age ≥65 years was associated with a shorter EFS and OS. In addition, patients with SMZL had a shorter OS than those with MALT. ASCT may provide clinical benefit in MZL patients who have failed multiple lines of chemoimmunotherapy.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfom z B-buněk marginální zóny $x diagnóza $x terapie $7 D018442
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a autologní transplantace $7 D014182
- 650 _2
- $a neúspěšná terapie $7 D017211
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Arcaini, Luca $u Universita Di Pavia, IRCCS Fondazione San Matteo, Pavia, Italy.
- 700 1_
- $a Ferretti, Virginia V $u IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
- 700 1_
- $a Boumendil, Ariane $u EBMT LWP Paris Office, Hôpital Saint-Antoine, Paris, France.
- 700 1_
- $a Finel, Hervé $u EBMT LWP Paris Office, Hôpital Saint-Antoine, Paris, France.
- 700 1_
- $a Milone, Giuseppe $u Institute of Hematology, University of Catania, Catania, Italy.
- 700 1_
- $a Zaja, Francesco $u DRMM, University of Udine, Udine, Italy.
- 700 1_
- $a Liliana, Devizzi $u Division of Medical Oncology, Istituto Nazionale dei Tumori, Milan, Italy.
- 700 1_
- $a Musso, Maurizio $u Oncoematologia e TMO, Palermo, Italy.
- 700 1_
- $a Didier, Blaise $u Département d'Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France.
- 700 1_
- $a Bachy, Emmanuel $u National Institutes of Health, National Cancer Institute, Bethesda, MD, USA.
- 700 1_
- $a Wattad, Mohammed $u Kliniken Essen Süd, Essen, Germany.
- 700 1_
- $a Nicolas-Virelizier, Emmanuelle $u Centre Léon Bérard, Lyon, France.
- 700 1_
- $a Gramatzki, Martin $u University Hospital Schleswig-Holstein, Kiel, Germany. University of Kiel, Kiel, Germany.
- 700 1_
- $a Bourhis, Jean-Henri $u Institut Gustave Roussy, Villejuif, France.
- 700 1_
- $a Caillot, Denis $u CHU de Dijon - Hospital `Le Bocage`, Dijon, France.
- 700 1_
- $a Haenel, Anette $u Klinikum Chemnitz gGmbH, Chemnitz, Germany.
- 700 1_
- $a Held, Gerhard $u Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany. University Hospital of Saarland, Homburg, Germany.
- 700 1_
- $a Thieblemont, Catherine $u APHP - INSERM U 728 - Institut Universitaire d'Hematologie, Hopital Saint-Louis, Paris, France.
- 700 1_
- $a Jindra, Pavel $u University Hospital, Pilsen, Czech Republic.
- 700 1_
- $a Pohlreich, David $u Charles University Hospital, Prague, Czech Republic.
- 700 1_
- $a Guilhot, François $u Inserm U935, CHU de Poitiers, Poitiers, France.
- 700 1_
- $a Kroschinsky, Frank $u Midizinische Klinik und Poliklinik I, Universitaetsklinikum Dresden, Dresden, Germany.
- 700 1_
- $a Wahlin, Björn $u Department of Medicine, Huddinge (MedH), H7, Unit for Hematology, M 54, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden.
- 700 1_
- $a Scheid, Christof $u GMMG, Germany, Cologne, Germany.
- 700 1_
- $a Ifrah, Norbert $u CHU d'Angers, Angers, France.
- 700 1_
- $a Berthou, Christian $u Brest University Hospital, Brest, France.
- 700 1_
- $a Dreger, Peter $u EBMT LWP Paris Office, Hôpital Saint-Antoine, Paris, France. University of Heidelberg, Heidelberg, Germany.
- 700 1_
- $a Montoto, Silvia $u Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
- 700 1_
- $a Conconi, Annarita $u Ospedale degli Infermi, Biella, Italy.
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 182, č. 6 (2018), s. 807-815
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29984825 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191008113233 $b ABA008
- 999 __
- $a ok $b bmc $g 1451796 $s 1073686
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 182 $c 6 $d 807-815 $e 20180709 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- LZP __
- $a Pubmed-20191007
